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ABSTRACT
Objective: COVID-19-related inequities experienced by racial and
ethnic minority groups including healthcare professionals mirror
wider health inequities, which risk being perpetuated by lower
uptake of vaccination. We aim to better understand lower uptake
among racial and ethnic minority staff groups to inform initiatives
to enhance uptake.
Design: Twenty-five semi-structured interviews were conducted
(October 2020–January 2021) with UK-based healthcare staff.
Data were inductively and thematically analysed.
Results: Vaccine decision-making processes were underpinned by
an overarching theme, ‘weighing up risks of harm against potential
benefits to self and others’. Sub-themes included ‘fear of harm’,
‘moral/ethical objections’, ‘potential benefits to self and others’,
‘information and misinformation’, and ‘institutional or workplace
pressure’. We identified ways in which these were weighted more
heavily towards vaccine hesitancy for racial and ethnic minority staff
groups influenced by perceptions about institutional and structural
discrimination. This included suspicions and fear around institutional
pressure to be vaccinated, racial injustices in vaccine development
and testing, religious or ethical concerns, and legitimacy and
accessibility of vaccine messaging and communication.
Conclusions:Drawing on a critical race perspective, we conclude that
acknowledging historical and contemporary abuses of power is
essential to avoid perpetuating and aggravating mistrust by de-
contextualising hesitancy from the social processes affecting
hesitancy, undermining efforts to increase vaccine uptake.
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Addressing racial and ethnic discrimination is vital to global efforts in defeating COVID-19
(Bhala et al. 2020). Data from the UK, US and Europe find racial and ethnic minority
groups have experienced disproportionately high rates of infection and mortality (Bhala
et al. 2020; Office for National Statistics 2021; Nazroo and Becares 2020; Valeriani et al.
2020). Multiple and inter-related proximal causes of such inequalities have been suggested.
For instance, Black, Asian and ethnic minority groups are more likely to experience chronic
health conditions, associated with poorer COVID-19 related outcomes (Williamson et al.
2020), and are more likely to live in overcrowded households and accommodation with
shared facilities or communal areas (Iacobucci 2020), in which COVID-19 is more prone
to spread (Cevik et al. 2020). Some racial and ethnic minority groups are more likely to
live in larger sized and multiple generation households for cultural, religious and/or afford-
ability reasons, making challenges with social distancing unavoidable (Martin et al. 2020).
They are also more likely to be employed as essential workers or less able to work from
home, and therefore experience a greater risk of exposure at work or commuting (Office
for National Statistics 2021). Underlying these more immediate risk factors is the cumulat-
ive impact of structural and institutional racism (Nazroo and Becares 2020).
Vaccine hesitancy
Widespread global access and timely uptake of COVID-19 vaccination is key to halting
the virus and minimising (or delaying) threat from new variants (Corey et al. 2020).
However, refusal or delayed COVID-19 uptake is potentially a major hindrance in dis-
tribution (Harrison and Wu 2020) and may exacerbate existing health inequalities.
Vaccine hesitancy is not specific to COVID-19, with differential uptake observed for
other vaccines (e.g. seasonal influenza) which disadvantage racial and ethnic minority
groups (Jain et al. 2017). Hesitancy is a ‘delay in acceptance or refusal of vaccination
despite the availability of vaccination services’ (MacDonald 2015, 4163), occurring on
a continuum from acceptance with no doubts to refusal with no doubts, with vaccine-
hesitant individuals existing between these two stances. The World Health Organiz-
ation’s (WHO) Vaccine Hesitancy Determinants Matrix (MacDonald 2015) acknowl-
edges contemporary and historic contextual factors affecting hesitancy and that people
may accept one vaccine while being hesitant about or declining another (Larson et al.
2014). However, it does not explicitly recognise or account for inequities in hesitancy
which may inform current attempts to equitably enhance uptake.
For the COVID-19 vaccine, such inequities have been evident for racial and ethnic
minority populations, for whom greater vaccine hesitancy has been found in the UK
(Freeman et al. 2020; Robertson et al. 2021; SAGE 2021) and internationally (Robinson
et al. 2020). There is concern that if acceptance is low among racial and ethnic minority
communities, COVID-19 will widen existing inequalities (SAGE 2021).
Vaccine hesitancy among healthcare staff
Addressing vaccine hesitancy and improving uptake among healthcare providers is a
global public health issue (Karafillakis et al. 2016; Paterson et al. 2016) because healthcare
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workers are disproportionately exposed to infection (Evans et al. 2020). Further, the
pressures of the pandemic and exposure to infection affect workplace absence and
morale, in turn placing an undue burden on health service capacity (Abbasi 2021;
Dacre 2021). Safety concerns; lack of vaccine knowledge or misinformation; lack of
awareness about national guidelines; beliefs that one’s own vaccination does not
benefit patients; concern about effectiveness and about necessity; societal endorsement;
and workplace peer support are all reasons for vaccine hesitancy identified among health-
care staff cited internationally (Yaqub et al. 2014; Paterson et al. 2016).
Available US-based evidence about the influenza vaccine finds lower uptake and/or
greater hesitancy among Black and Latinx healthcare staff groups (e.g. Lu et al. 2014).
Racial and ethnic minorities are overrepresented within the UK healthcare workforce
and may be expected to have lower institutional and vaccine trust given greater perceived
discrimination and distrust within and outside of the health service (Rhead et al. 2020;
Polling et al. 2020). They also disproportionately experience occupational exposure to
(Pan et al. 2020) and deaths from COVID-19 amongst staff (Evans et al. 2020).
However, there is little available evidence about mechanisms underpinning COVID-19
vaccine hesitancy among racial and ethnic minority healthcare staff to inform approaches
to better support decision-making around vaccine uptake. This study therefore specifi-
cally addresses the following questions:
(1) How do healthcare staff make decisions about taking up a COVID-19 vaccine?
(2) How are these decision-making processes experienced by racial and ethnic min-
ority healthcare staff groups, and how this is influenced by racism and discrimi-
nation?
Materials and methods
Qualitative data were collected from two samples during phase two of the Tackling
Inequalities and Discrimination Experiences in health Services (TIDES) study (www.ti-
desstudy.com), a UK-based project aiming to identify inequalities in health service use
and exploring discrimination experienced by healthcare staff and service users (Rhead
et al. 2020). Phase two was initiated in July 2020 to examine the national impact of
COVID-19 on inequalities experienced by racial and ethnic minority health and social
care staff groups. This was developed with and guided by a modified Delphi consensus
process (Linstone and Turoff 1975) with an expert panel (advisory group) comprising
clinical academics, health and social care staff and senior leaders, and a wider stakeholder
opinion group of health and social care staff across England.
Context
Data were collected between October 2020 and January 2021, when COVID-19 infection,
hospitalisation and death rates rapidly rose twice across the UK, putting unprecedented
strain on health and social care services. Data collection coincided with the rapid devel-
opment and approval of initial COVID-19 vaccinations amidst widespread media cover-
age and discussion about the process of vaccine development, as well as government
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indications for how and when the vaccines would be rolled out. Data collection began just
prior to roll-out and continued during the initial roll-out phases.
Participants and sample selection
Healthcare staff (HCS) sample
Healthcare staff initially took part in the TIDES phase one survey (n = 931) detailed else-
where (Rhead et al. 2020) and subsequent qualitative interviews (n = 46), including
student nurses, healthcare assistants, and qualified nurses within the NHS recruited
January 2019–February 2020. Staff agreeing to be recontacted (n = 45) were purposively
sampled for phase two to include both racial and ethnic minority and white British staff
across seniority levels. Criteria were based on evidence indicating differential exposure to
discrimination by seniority and race/ethnicity and poorer career progression among
racial and ethnic minority groups (NHS Equality and Diversity Council 2019). The
current study includes TIDES phase two data.
Senior management sample
We combined snowball and key informant sampling (Marshall 1996) for TIDES phase
two. Our targeted sampling approach included: high-level management from national
health bodies, senior-level clinicians with management responsibilities; and non-clinical
senior-level staff in equality, diversity & inclusion (EDI)-related roles. Advisory and sta-
keholder opinion groups helped identify potential key informants meeting these criteria.
Of those, we prioritised recruitment to incorporate both racial and ethnic minority and
White British participants nationally. Senior sample recruitment was continued along-
side iterative data analysis until saturation.
Recruitment
Recruitment and data collection occurred between October 2020 and January 2021.
Potential participants received an e-mail invitation. Those expressing interest were
sent an information sheet with details about data confidentiality and study withdrawal.
Three maximum further contact attempts were made. Participants recruited were
assigned a unique ID number to complete a digital consent form prior to interview. Par-
ticipants provided socio-demographic information (gender, race and/or ethnicity,
migration status, religion) and were offered £15 shopping vouchers in appreciation for
their time.
Data collection
Online semi-structured interviews (45–60 minutes) were recorded with consent. Topic
guides were developed and refined with advisory and stakeholder opinion groups. Inter-
view domains covered racial and ethnic inequalities experienced by staff (e.g. witnessing
and experiencing workplace discrimination, bullying and harassment). Current analyses
focus on data pertaining to questions and probes about COVID-19 vaccination (e.g.
beliefs about uptake and implementation; vaccine and roll-out concerns).
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Healthcare staff interviews were conducted by experienced TIDES qualitative
researchers. External EDI experts with experience in interviewing NHS managers con-
ducted senior management interviews. Data were transcribed verbatim, removing iden-
tifying information.
Ethical approval
Ethical approval was granted by the King’s College London Research Ethics Committee
for Psychiatry, Nursing and Midwifery (HR-17/18-4629; RESCM-19/20-4629; RESCM-
20/21-4629) and NHS Health Research Authority (18/HRA/0368).
Analysis
Data were analysed thematically using an inductive approach (Braun and Clarke 2012)
by a racially, ethnically and gender diverse research team. Following familiarisation,
one researcher descriptively coded transcripts, using these to develop an initial
coding framework. Two other researchers descriptively coded a subset of the tran-
scripts, together discussing and refining the coding framework, applying it to all tran-
scripts after inputting into NVivo (QSR International Pty Ltd 2018) to support data
management. No major interpretative differences were raised, but nuances were devel-
oped through discussion. Codes were grouped into themes reflecting key patterns in
the data relevant to the research questions, continually checking and refining against
the raw data, actively looking for similarities and differences both within and across
datasets, and looking for patterns by participant characteristics. Themes were
defined, described and labelled. Patterns between themes and our narrative interpret-




The analytic sample included 17 healthcare staff and eight senior management members.
Of 25 participants, nearly three-quarters identified as female, two-thirds identified as a
racial or ethnic minority group, over a third were born outside the UK and three-quarters
specified a religious faith. Qualified nurses and senior clinicians each comprised two-
fifths of the sample, the remainder were students, healthcare assistants or EDI specialists.
Around two-thirds of interviews occurred just before, and a third just after roll-out of
COVID-19 vaccinations in the UK (Table 1).
Vaccine stance: accepters, decliners and hesitants
Participants’ vaccine stances lay on a continuum from those who would immediately
accept if offered or had already been vaccinated (herein referred to as ‘vaccine accepters’),
to those who were certain that they would decline (‘vaccine decliners’). Between these
stances were people defined as ‘vaccine hesitant’. Hesitancy reflected a nuanced stance,
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from those who reported feeling undecided to those likely to accept eventually but
wanted to wait and see before deciding. Just over half of participants were vaccine accep-
ters, over a third expressed hesitant views, while a minority reported that they would
decline.
I wouldn’t be the first one to go for the vaccine, but I might be the 10th or the 11th, or the
100th if that makes sense. (Hesitant, Asian, senior clinician, before roll-out)
We also asked participants whether they thought any staff groups would be (or were
experienced as) more or less likely to take up the vaccine. Among those identified were
staff who would normally decline the influenza (‘flu) vaccine (e.g. due to underlying
health conditions or other potential risk factors like pregnancy); and that racial and
ethnic minority groups may be (or were, following roll-out) particularly hesitant (or ‘sus-
picious’) about vaccine uptake. To help untangle the underlying causes of hesitancy and
suspicion, we describe the decision-making process within one overarching theme,
‘weighing up risks and benefits for self and others’.
Weighing up risks and benefits for self and others
For those hesitant about the vaccine, decision-making was described as an active apprai-
sal process, a balancing act and personal decision requiring calculation of potential risk
from the vaccine and from COVID-19, against the potential benefits of being vaccinated.
Importantly, this stance was not necessarily static.
I was neutral for a long time on it and only last week, I made a decision to have the vaccine
and I’ve had it and um[…] I weighed up the evidence and come to that decision for myself.
But as I say, it is a personal thing that people have to decide for themselves. (Accepter, Black
Caribbean, senior management, after roll-out)








Black African 2 8
Black Caribbean 4 16
White British 11 44






Religion specified 18 72
Specified no religion 6 24
Sample
Healthcare staff 17 68
Senior management 8 32
Timing
Before UK vaccine roll-out 16 64
After UK vaccine roll-out 9 36
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Some immediate accepters also referred to this weighing up process but the balance
more clearly favoured vaccination. Parameters influencing these calculations were rep-
resented by the sub-themes ‘fear of harm’, ‘moral or ethical objections’, ‘potential
benefits to self and others’, ‘information and misinformation’, and ‘institutional or work-
place influence’. Comparing vaccine stances, decliners focussed on perceived risk (fear of
harm to self) and less on benefits to self and others. In contrast, hesitants described both
fears of harm (particularly unknown long-term effects) as well as benefits to self and
others, equally. Accepters also described fears but primarily in relation to what they
had heard other’s say; instead, they most commonly focussed on vaccination benefits.
Fear of harm
This theme referred to fears about harm, influenced by perceived trust in the vaccine,
personal vulnerability and risk, as well as precedence and past experience. Harm included
immediate side effects such as adverse health impacts for people with underlying con-
ditions (whether known or to be revealed only after being vaccinated), developing
COVID-19 symptoms and, particularly, fears of longer-term effects. Such effects were
often unspecified but included, for example, birth defects or effects on fertility.
Trust in the vaccine
Fears of harm were grounded primarily in reservations about the speed of vaccine pro-
duction, trialling and implementation. Participants had strong perceptions that fast-
tracking may have led to corner-cutting, lack of robust testing and inaccurate assess-
ments about the risk of side effects and/or effectiveness against COVID-19. Allied to
these fears was a perceived lack of sufficient research or clinical evidence. Specifically,
concerns about longer-term side effects were underpinned by perceived lack of longitudi-
nal data on its effects. Such doubts were mentioned by the majority of hesitants, all decli-
ners but none of the accepters.
I wouldn’t take it up if offered, um. I’m quite dubious of taking a vaccine that’s only been
trialled for about 9, I don’t even know, 9 months? And I think medications need to look at
not only the short-term effects but the longitudinal effects of taking a vaccine medication.
Um as a young woman of fertile age I don’t want anything that could potentially either
harm any fertility maybe in the future. (Decliner, Black African, HCS, before roll-out)
A vaccination that should have taken 10–20 years to develop and test properly has been pro-
duced in a matter of months. And, um… so it hasn’t been -it hasn’t been tested and it hasn’t
been scrutinised the way it should have been. (Hesitant, Black Caribbean, HCS, after roll-
out)
While some accepters acknowledged concerns about fast-tracking, in contrast, some
expressed particular confidence in the development process.
I’m fine with it, like I mean it’s been approved in this country, it’s been approved in other
countries now as well, like. I mean I have the flu vaccine every year and like we’ve had
patients who have bought into the anti-vaxx stuff, but. You know, we’re medical pro-
fessionals so we shouldn’t be getting drawn into that. (Accepter, White British, HCS,
before roll-out)
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Among certain participants, vaccine mistrust reflected mistrust in government and
pharmaceutical companies. For some racial and ethnic minority staff, particularly
Black African and Black Caribbean and other Black groups, suspicion and mistrust in
the vaccine development process was particularly salient, grounded in fears and recollec-
tions of experiences related to poor and unethical research practise.
BME staff have been less likely to opt into receiving the vaccine […] I think there’s
something around how… If you look at things historically, Black and Asian communities
have been misused in research […] we have been abused and violated in previous vac-
cination trials and we can’t deny that. (Decliner, Asian, senior management, after roll-
out)
Trust also related to beliefs about vaccine effectiveness and uncertainty surrounding
protection against transmission. Some participants questioned whether there was
sufficient evidence on vaccine efficacy to warrant the immediate and personal risk of
being vaccinated; which coincided with a lack of clarity about the available information.
For instance, media reporting headline figures about varying vaccine efficacy was a
source of considerable uncertainty.
I know this coronavirus is gonna mutate into another virus at some point anyway, so you
know, if it’s going to be 21, coronavirus 21, and. If you’ve been vaccinated this time
around will it fight the coronavirus um will it fight coronavirus 21? (Hesitant, White
British, HCS, before roll-out)
I haven’t really seen a lot of, information on it yet or done a lot of research on it just kind of
what I’ve seen on TV and stuff, um but I mean. I guess it can only be a good thing if it stops it
from getting worse in the future. I know it’s only about 90% accurate, whatever. (Accepter,
Asian, HCS, before roll-out)
Uncertainty also highlighted a margin of error into which some participants worried
that they might personally fall.
Personal vulnerability and risk
For some, worries about adverse effects of the vaccine tended to be linked to specific pre-
existing vulnerabilities. In participants classified as decliners, this reflected unease about
known underlying health conditions also affecting uptake of other vaccines.
So when the vaccine coming now, I say no I will not- I need to read, I need to know 90%
for me you know it, it could be that you know especially my system’s rubbish, I have
vitamin D deficiency, I have anaemia now, I don’t know why. So you know my body
has, I don’t know whether to fight the new thing. (Decliner, Other ethnic group, HCS,
before roll-out)
Among hesitants, there were common concerns that unknown personal vulnerabilities
may arise leading them to experience harm from vaccination.
I spoke to my wife about it and because we have a 5-year old son. She’s like to me, one
of us should have it and one of us should not have it because then we’re covering both,
you know, if anything happens - and I grow an extra limb [laughs], I’m exaggerating
again. I don’t know, something might happen within my respiratory - I might be
more prone to respiratory illness or whatever it might be. (Hesitant, White British,
HCS, before roll-out)
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Precedence and past experience
Other grounds for apprehension were related to prior experiences of vaccines or treat-
ment which had – only after widespread roll-out – been found to cause more widespread
harm (e.g. Thalidomide).
I don’t know if it would but you know like, I guess it’s different but like [drug name] for our
patients like they only just found out that that has birth defects and can cause disabilities.
(Decliner, Black African, HCS, before roll-out)
Both hesitants and decliners raised negative past vaccine experience as a source of
doubt. In contrast, accepters all referred to past experience in a normalising way – com-
paring the COVID-19 vaccine to the ‘flu or other routine vaccines for healthcare staff.
When I joined the Trust I had to go through occupational health and have a whole load of
vaccines. So I feel like it’s just going to be another one added in. (Accepter, White British,
HCS, before roll-out)
It was frequently mentioned that COVID-19 vaccine hesitancy or decline is not
necessarily unexpected because it also commonly occurs with the ‘flu vaccine, which is
routinely offered to healthcare staff.
A lot of people don’t have the flu vaccine for example, and not putting race against the flu
vaccine but I’m just saying that a lot of people, whatever race they are, they don’t take the flu
vaccine, and there will be this COVID vaccine where people won’t take the COVID vaccine.
(Hesitant, Asian, HCS, before roll-out)
Religious or ethical objections
The second theme influencing the decision-making process was ‘religious or ethical
objections’. This was less commonly endorsed by participants and tended to be cited
about other people’s stance rather than their own.
A lot of people um use kind of religious reasons for not taking it. Um ‘cause there was some-
thing in the news today about some of the components of the vaccine is um, genes from kind
of unborn babies or something crazy like that so, a lot of religious people will not take the
vaccines for those sorts of reasons. (Accepter, Asian, HCS, before roll-out)
Some staff just are hesitant, and you would say that some of our BAME staff particularly are
very hesitant – even, and in the matter of fact, the ones who are even high risk really very
high risk, shielding, even they - some of them are still reluctant. That comes out quite
strange, but you know it might be something to do with cultural beliefs. (Accepter,
Asian, senior management, after roll-out)
We explored variation by reported religiosity; hesitants and accepters were fairly
evenly split across those who did or did not identify themselves as being religious
though decliners did identify as religious. However, there were no clear patterns when
examining reasons for hesitancy or refusal and decliners did not cite religious or
ethical objections as affecting personal decision-making.
Potential benefits to self and others
Accepters and hesitants tended to focus more on the potential benefits of vaccination
to themselves and others. This included protecting yourself from the virus,
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protecting other people by reducing the likelihood of transmission, and more broadly
supporting the effort to halt disease spread. Vaccine development and uptake were
frequently positioned as key to facilitating and expediting a return to pre-COVID-
19 life. While accepters included participants from across seniority levels, senior
nursing and management staff particularly emphasised the importance of protecting
others.
Protecting yourself and others
While protecting oneself from contracting COVID-19 was discussed, there was also a
corresponding sense of moral or social responsibility (a ‘duty of care’) – protecting
yourself would also protect others. This motivation reflects concerns about bringing
infection home or to vulnerable people outside work, as well as patients. There was
acknowledgment and shared endorsement of others’ concerns about potential
risks; however, some also expressed explicit disapproval or judgement for vaccine
decliners, labelling such a decision as ‘selfish’ for prioritising personal preference
or concerns.
It’s not all about me, I may be a healthy person but obviously all the vulnerable people, so we
might be carrying something that is deadly for them. Who knows, it might be deadly for my
kids. Me protecting myself is not just about protecting myself, it’s about whoever surrounds
me as well. (Accepter, White Other, HCS, before roll-out)
Direct exposure to the impact of COVID-19 while treating patients, and reflected in
intensified workplace pressures since the outbreak, contributed to a sense of urgency.
This was a strong counterbalance against fears about potential harm.
I can imagine the majority of staff will take it, especially in the healthcare setting because you
see a lot of it first-hand how it’s affecting people so I can’t imagine a lot of people would say
no to it. (Accepter, Asian, HCS, before roll-out)
From the worker perspective I suppose there is this um, obligation in many respects to have
the vaccine to make sure that you are reducing the risk of either contracting COVID yourself
or spreading COVID in the health service, given the pressures that we’re under. (Hesitant,
Asian, HCS, before roll-out)
Hesitants also discussed potential benefits related to the protection of self and others
and a similar moral stance. However, more so than for accepters, this tended to be
caveated as dependent upon reports of vaccine effectiveness. Some participants also
cited uncertainty about the necessity of vaccination (e.g. being currently fit and
healthy or having already had the infection). There was some indication that staff not
working in direct patient care may also need more convincing of the personal benefits
of vaccination.
I think I would probably get it, just because… I’ve had it [COVID-19] before I know there’s
some kind of like, resistance to the antibodies at the beginning but then they say that the
antibodies decrease and you’re not really protected anymore from a second infection. So
I know that I would be at risk again and that I should probably have it. But it is just kind
of weighing up like, am I likely to get it again or what could be the long-term effects of
these vaccines I don’t know, but I’m still undecided. (Hesitant, White British, HCS,
before roll-out)
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Getting back to normality
Another key rationale for accepting vaccination was to get back to normality. This was
endorsed mainly by accepters and only one hesitant, who wanted to travel to see
family. They felt that this involved a kind of social contract, relying on other people
also being vaccinated for it to work.
We have to go back to normal. We have to start visiting our families again, and it’s for our
patients as well. And then you need like, for it to work you need a percentage of the popu-
lation to be getting the vaccine, otherwise it won’t. It won’t work. (Accepter, White Other,
HCS, before roll-out)
Information and misinformation
Fears of harm, beliefs about benefits to self and others and, to some extent, religious
or ethical objections, were all affected by uncertainty. This arose from suspicions
about fast-tracking and a perceived lack of research evidence as described above,
but also from the nature and sources of information available about the vaccine,
which many felt lacked clarity. For hesitants and decliners, in particular, a lack of
trustworthy information left a void into which doubt could be fuelled by media
speculation and misinformation. There was mistrust that information could be
manipulated to fit government or institutional agendas, alongside confusion about
messaging.
I guess if the government agenda is for the vaccine to be rolled [out], definitely there
are going to be manipulation within the news. (Hesitant, White Other, HCS, before
roll-out)
This was a key area in which racial and/or ethnic minority staff, particularly those
experiencing language barriers, may be affected. Trust in vaccine information is
affected by historical abuses as alluded to earlier but also by how relatable and accessible
that information is and it’s source.
It’s understanding people’s cultures and being culturally competent, culturally aware. And
having, you know, people speaking to their own communities. Um people who are in pos-
itions like myself speaking to your own communities and family members to give out posi-
tive messages to the family members and wider community to say actually, I would take the
COVID vaccine and therefore you should be doing it as well. Um and these are the benefits
and these are the risks. But if you’re going to get somebody else who doesn’t look like you,
doesn’t sound like you, doesn’t speak your language; that trust is not there, necessarily.
(Hesitant, Asian, HCS, before roll-out)
Many participants, particularly accepters and hesitants, were careful to distance them-
selves from ‘anti-vaxxers’, referring to those who reject all vaccinations for reasons
including conspiracy theories. For some, this came with a sense of social desirability
about being vaccinated – highlighting that they were usually pro-vaccine, first in line
to get the ‘flu jab or would encourage others to be vaccinated if they were prevented
by health reasons.
I’m still holding the point that I’m always against all these anti-vaxxers saying oh this is just
a, you know, something that er vaccine companies or pharmaceutical companies have
created just to get some more money. (Accepter, White Other, HCS, before roll-out)
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Institutional or workplace influence
Institutional or workplace influence could vary in intensity from making vaccination obli-
gatory, putting ‘pressure’ on, or ‘encouraging’ staff or specific groups to accept. Hesitants
and decliners discussed institutional influence very differently to accepters. The former –
talking mainly before or just at the start of vaccine roll-out – expressed worries about being
‘forced’ by employers to be vaccinated. This was reinforced by media speculation and
workplace rumours about whether there would be sanctions from employers (e.g. job
loss, redeployment from patient-facing roles) or government (e.g. travel restrictions) if
they declined. Mandating and being ‘forced’ was a worry because it would restrict auton-
omy in ‘weighing up’ their vaccination decision. Others pointed to the unfairness about
being forced to take something with a perceived limited evidence-base.
I don’t think it’s fair to force people to take something that’s only been trialled and tested for
six months. (Decliner, Black African, HCS, before roll-out)
Accepters discussed mandating the vaccine differently. With the exception of one
senior clinician who strongly supported mandating the vaccine, others in this group
(mainly in the healthcare staff sample) were ambivalent or expressed resignation about
the prospect – expecting not to have a choice or to experience pressure.
I think I’d be kind of crazy not to, I’d almost feel like they’re going to make it mandatory
anyway, I’d imagine they would not make it an option to take it. (Accepter, Asian, HCS,
before roll-out)
Such resignation was not mirrored by senior management who (talking mainly after
the onset of vaccination) emphasised the importance of personal choice and anticipated
push-back to mandatory vaccination.
People are making an informed choice um- but I don’t think we can mandatory- I think
there’d be- I think there’d be um- civil war if we’d mandated that people get jabbed with
this virus- with the vaccine. (Accepter, White British, senior management, after roll-out)
Nonetheless, participants from all vaccine stances expected to receive direct and indir-
ect forms of ‘pressure’ or proactive ‘encouragement’ from their organisation to be vacci-
nated. Several participants anticipated racial and ethnic minority staff groups would be or
feel particularly pressured (or encouraged) to take it up.
Because people from um BME backgrounds have been identified as higher risk they could
potentially also be more pressured into getting it, of getting the vaccine? And perhaps they
um, they wouldn’t want it for their own personal reasons, but then my worry and also I think
a lot of people’s worry at the moment is what is the NHS going to say in terms of getting the
vaccine; is it going to mandatory, are people going to be threatened with, you know, job loss
or that kind of thing if they don’t want to get it. (Hesitant, White British, HCS, before roll-
out)
There was an expressed sense from some participants that putting pressure on racial
and ethnic minority staff groups, however well intended, was likely to fuel suspicion
and resistance.
Someone said, ‘oh you know they going to force us to have it’, I go ‘no no I’m not going to
have any vaccine’, you know when they talking they say oh they are going to force us- I said
‘no one can force us to have anything’. (Decliner, Other ethnic group, HCS, before roll-out)
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Alternatively, approaches which encouraged uptake (through targeting messages, pro-
viding information directly addressing specific concerns raised by racial and ethnic min-
ority staff, and leveraging social norms) were expected to yield greater success.
We’ve got a number of our senior staff that have had the jab that are – that we’re using in
promotions to say you know, like doctors, consultants and um other sort of more sort of
more senior nurses that are BAME to say, ‘I’ve had my jab done, get yours done’. (Accepter,
White British, senior management, after roll-out)
Moreover, not involving affected staff in efforts to promote uptake may limit the effec-
tiveness of campaigns.
I’m not sure if they’ve done any particular work with the BME staff network to understand
why people might be apprehensive about the vaccine. There’s not been any direct kind of
involvement, or them reaching out to understand what the issue is. (Decliner, Asian,
senior management, after roll-out)
Discussion
We qualitatively explored views about COVID-19 vaccination among healthcare staff to
better understand influences on decision-making, particularly among racial and ethnic
minority staff groups. A single overarching theme explained vaccine decision-making
as a process of weighing up potential risk and benefits for themselves and for others.
Five sub-themes reflected key influential parameters: fear of harm; religious and/or
moral objections; potential benefits to self and others; information and misinformation;
and, institutional or workplace pressure. While aspects of each theme overlapped with
concerns reported in general population studies (e.g. fears about side effects and fast-
tracking, beliefs in vaccine effectiveness), participants also highlighted influences
specific to healthcare staff (e.g. duty of care, institutional/workplace pressure, exposure
to the impact of infection, experience with other routinely offered vaccines at work).
Some of these were particularly pertinent for racial and ethnic minority group staff,
who also experienced additional inter-related grounds for vaccine hesitancy.
This included suspicions and fear around being pressured to be vaccinated, racial
injustices in vaccine development and testing, religious or ethical concerns, and legiti-
macy and accessibility of vaccine messaging and communication. Except religious/
moral objections (only reported indirectly), all these factors reflected greater mistrust
in institutions involved in vaccine promotion. We take a critical race theory perspective
(Crenshaw et al. 1995), discussing how racism and racialised stratification processes
underpin observed and anticipated inequities in vaccine hesitancy; result in influences
affecting hesitancy common to the wider population being weighted more heavily for
racial and ethnic minority groups; as well as provoking additional grounds for hesitancy.
Furthermore, we consider how discriminatory social processes also influence the efficacy
of interventions designed to enhance vaccine uptake.
Comparisons with previous literature
Limited available evidence suggests lower vaccine uptake among Black healthcare staff is
due to higher levels of vaccine concern (Ojha et al. 2015). While aligned with our findings
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and helping identify putative targets for enhancing uptake, such concerns were reported
by healthcare staff across racial and ethnic groups in our study and mirror mechanisms
underpinning vaccine hesitancy generally (Freeman et al. 2020; Larson et al. 2014; Peprah
et al. 2016). Moreover, it leaves the question of why they hold these concerns to a greater
extent. In response, we draw on aspects of the ‘Vaccine Hesitancy Determinants Matrix’
(MacDonald 2015) which were raised by participants (Table 2).
Contextual influences
Our findings illustrate the salience of contextual influences on vaccine hesitancy among
racial and ethnic minority groups. This is supported by research among US African dia-
spora communities, identifying issues such as government and pharmaceutical company
mistrust, prior racial injustices linked to unethical research, social media misinformation,
and concerns about vaccine prioritisation being experimentation (Ateghang-Awankem
and Anchang 2020). UK-based research indicates trust in COVID-19 information
received from government, scientists and health-related institutions is lower among
Black, Asian and minority ethnic groups (Wellcome Monitor 2020) and mistrust is
associated with COVID-19 vaccine refusal or hesitancy (Murphy et al. 2021).
Mistrust is grounded in wider inequalities beyond COVID-19; racial and ethnic min-
ority groups are more likely to experience socio-economic disadvantage, exposure to and
anticipation of discrimination throughout their lives and across generations (e.g. Rhead
et al. 2020; NHS Equality and Diversity Council 2019; Williams and Cooper 2020). Since
Table 2 . World Health Organization’s Vaccine Hesitancy Determinants Matrix (reproduced from
MacDonald 2015, 4163).
Contextual influences
Influences arising due to historic, socio-cultural,
environmental, health system/institutional, economic or
political factors
(a) Communication and media environment
(b) Influential leaders, immunisation programme





(g) Perception of the pharmaceutical industry
Individual and group influences
Influences arising from personal perception of the vaccine
or influences of the social/peer environment
(a) Personal, family and/or community members’
experience with vaccination, including pain
(b) Beliefs, attitudes about health and prevention
(c) Knowledge/awareness
(d) Health system and providers – trust and personal
experience
(e) Risk/benefit (perceived, heuristic)
(f) Immunisation as a social norm vs. not needed/harmful
Vaccine/vaccination – specific issues
Directly related to vaccine or vaccination
(a) Risk/benefit (epidemiological and scientific evidence)
(b) Introduction of a new vaccine or new formulation or a
new recommendation for an existing vaccine
(c) Mode of administration
(d) Design of vaccination programme/Mode of delivery
(e.g. routine programme or mass vaccination campaign)




(h) The strength of the recommendation and/or
knowledge base and/or attitude of healthcare
professionals
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the outbreak, intensified awareness of disproportionate infection and death rates likely
serves as a constant reminder of the structural and institutional racism underpinning
these inequalities.
The legacy of medical experimentation and unethical research, including neglect and
lack of accountability for adverse effects, on racially minoritised communities, further
exacerbates mistrust in Western pharmaceutical companies and vaccines (Washington
2006; Jegede 2007; Scharff et al. 2010; Centres for Disease Control and Prevention
2020). This includes publicised suggestions about the experimentation of COVID-19 vac-
cines in Africa (BBC News 2020).
We found messaging and communication also influenced vaccine hesitancy. Public
health messaging not tailored or relatable to different racial and/or ethnic communities
may add, or fail to address uncertainty, confusion and vaccine mistrust, and reduce infor-
mation accessibility (Ojha et al. 2015). In the UK, White Other, Asian and particularly,
Black and mixed racial/ethnic groups are less likely to report finding information about
COVID-19 clear compared to White British respondents (Wellcome Monitor 2020). Our
findings illustrate that this does not reflect ‘lack of understanding’ but perceived legiti-
macy of the communication and (for some) language barriers, reinforcing the impor-
tance of communication from members of their own communities (SAGE 2021).
Media misinformation was reported to exacerbate this, particularly impacting faith com-
munities’ concerns about vaccine constituents (Sherwood 2021).
Individual and group influences
As supported by our findings, social and peer influences include prior experience of
knowledge and awareness about, and perceived risks and benefits of vaccination. Pre-
viously identified misconceptions among US-based African diaspora, such as the
vaccine weakening their already strong enough immune systems to combat infection,
further exemplify the need for nuanced uptake initiatives (Ateghang-Awankem and
Anchang 2020). Further, trust in the health system and vaccine providers influences
the extent to which immunisation is a social norm within communities, perceived as
unnecessary or even harmful (MacDonald 2015). Lack of inclusion of racial and ethnic
minority groups in research (Treweek et al. 2020), also likely raises concerns about the
applicability of effectiveness and safety evidence.
Vaccine or vaccination-specific influences
Reasons for hesitancy related specifically to vaccines or the vaccination process mainly
pertained to suspicions about fast-tracking, pressure to be vaccinated, and perceived
legitimacy of the evidence-based. Racial and ethnic minority staff groups may be more
influenced by these factors due to the above issues, as well as prior adverse experiences
with premature vaccine distribution (e.g. Sanofi’s dengue vaccine) (Dyer 2019).
Strengths and limitations
Limited research exists examining vaccine hesitancy specifically among racial and ethnic
minority groups, resulting in little evidence on hesitancy reduction interventions to draw
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on (SAGE 2021). We examined COVID-19 vaccination perceptions using timely data
collected just prior to and after the UK vaccine roll-out. Nested within an ongoing
project examining the impact of COVID-19 on inequalities experienced by racial and
ethnic minority healthcare staff, our research was well placed to examine vaccine hesi-
tancy and lower uptake. Although a key strength, the immediacy and severity of the
issue may have influenced how participants framed their responses. It is possible that
social desirability influenced senior management interviews conducted at vaccine roll-
out outset – the need to set an example, and/or alignment with institutions promoting
uptake. Interviews before roll-out may have reflected wider uncertainty about oper-
ational processes. As with other qualitative studies, we cannot claim generalisability;
however, findings do support and refine existing theory and evidence underpinning
vaccine hesitancy. Our study was developed with healthcare staff and interpretations
have been refined through discussion among a racially and ethnically inclusive team of
researchers and healthcare practitioners.
Implications
Findings suggest that existing vaccine hesitancy models may need to be developed further
in relation to racial and ethnic minority and religious communities for whom recognised
influences are shaped by discriminatory social and institutional processes affecting mis-
trust. Findings also emphasise the importance of considering intersections between race/
ethnicity, language, age, gender and parenthood. For enhancing uptake, we suggest no
single approach will encourage uptake among racial and ethnic minority communities
and healthcare staff, and support recommendations focussing on increasing trust and
influencing social norms (UK Scientific Advisory Group for Emergencies (SAGE)
2021) and taking into consideration prior evidence on adapting public health interven-
tions to racial and ethnic minority populations (Davidson et al. 2013). This involves col-
laborating with community-based organisations to develop tailored messaging and
vaccine delivery through trustworthy and legitimate channels; targeted educational cam-
paigns addressing specific vaccine concerns; and increased accessibility through commu-
nity and workplace-based delivery. Our results indicate that meaningful and respectful
community engagement and acknowledgment of historical and contemporary abuses
of power is key.
For healthcare staff, our findings indicate that approaches to encourage uptake (e.g.
promotional materials, engaging racial and ethnic minority staff groups to address
specific concerns, and in-house vaccinations) may help increase trust through peer
social norms and greater convenience. However, they are unlikely to be sufficient
without acknowledging, validating and actively counteracting deep concerns linked to
past and ongoing discrimination. Our study also indicates the centrality of personal
decision-making; discriminating against hesitant staff will likely further alienate and
intensify mistrust, undermining attempts to increase uptake.
Conclusions
Lower COVID-19 vaccine uptake among racial and ethnic minority groups risks exacer-
bating health and social inequalities. Concerns tipping the balance towards vaccine
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hesitancy are weighted more heavily for these groups for reasons broader than the vac-
cination itself. Instead of generalised approaches to encouraging uptake, they should be
tailored to the nuanced concerns within and between different groups; transparent in
acknowledging the root causes of concerns; and considerate of intersectional social sta-
tuses. Importantly, approaches must avoid perpetuating and aggravating mistrust by de-
contexualising hesitancy from underpinning social processes and not disproportionately
pressuring, discriminating, or shaming marginalised communities for being hesitant.
Community-led and engaged approaches are key though must be supported by commit-
ments to address fundamental causes of COVID-19 inequalities rather than laying
responsibility on those most affected.
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